托特罗定联合硝苯地平治疗女性膀胱过度活动症的疗效观察

目的探讨托特罗定联合硝苯地平治疗女性膀胱过度活动症（OAB）的疗效。方珐女性OAB患者60例，随机分为2组：A组（30例，托特罗定片2mg，2次／d，连服4周），B组（30例，托特罗定片并硝苯地平片，5mg，3次／d，连用4周）。治疗前及结束后行ABSS评分。结果A组患者治疗前后尿急评分分别为（3．6±1．O）与（1．8±O．5）分，OABSS评分分别为（10．9±4．8）与（5．3±1．8）分；B组患者治疗前后尿急评分分别为（3．7±0．9）与（O．8±0．1）分，OABSS评分分别为（10．8±1．8）与（3．8±1．7）分，2组治疗前后差异均有统计学意义（P〈0．05），2组治疗后尿急评分和OABSS评分差异有统计学意义（P〈0．05）。结论托特罗定联合硝苯地平治疗女性膀胱过度活动症效果较好。

Efficacy of Tolterodine combined with Nifedipine in female patients with overactive bladder

Objective To evaluate the efficacy of Tolterodine combined with Nifedipine in female patients with overactive bladder （OAB）. Methods 60 female patients with OAB were randomly divided into two groups with 30 patients. Patients in Group A received tolterodine 2 mg bid for 4 weeks. Patients in Group B received Tolterodine combined with Nifedipine 5 mg tid for 4 weeks. During the treatment all patients recorded voiding and adverse reactions in a diary. The symptoms of urgency, frequency and incontinence were evaluated with OABSS scores at the beginning and the end of the therapy period. The results of the efficacy were analyzed with SPSS 13.0. Results The OABSS scores at the beginning and the end of therapy for the two groups were significantly different （P〈0.01）. The OABSS scores at the end of the therapy between the two groups were significantly different （P〈0.05）. Patients in Group B had better results than patients in Group A. Conclusion Tolterodine combined with Nifedipine is more effective than Tolterodine alone in the treatment of female OAB.